Literature DB >> 25678637

Infectious diseases. Ebola drug trials lurch ahead.

Kai Kupferschmidt, Jon Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25678637     DOI: 10.1126/science.347.6223.701

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  7 in total

Review 1.  Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Authors:  Gary Wong; Gary P Kobinger
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

2.  Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection.

Authors:  Stuart David Dowall; Jo Callan; Antra Zeltina; Ibrahim Al-Abdulla; Thomas Strecker; Sarah K Fehling; Verena Krähling; Andrew Bosworth; Emma Rayner; Irene Taylor; Sue Charlton; John Landon; Ian Cameron; Roger Hewson; Abdulsalami Nasidi; Thomas A Bowden; Miles W Carroll
Journal:  J Infect Dis       Date:  2015-12-28       Impact factor: 5.226

Review 3.  Decoding the enigma of antiviral crisis: Does one target molecule regulate all?

Authors:  Abdullah Mahmud-Al-Rafat; Apurba Majumder; K M Taufiqur Rahman; A M Mahedi Hasan; K M Didarul Islam; Andrew W Taylor-Robinson; Md Morsaline Billah
Journal:  Cytokine       Date:  2019-01-04       Impact factor: 3.861

4.  Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome.

Authors:  Hao Li; Xia-Ming Jiang; Ning Cui; Chun Yuan; Shao-Fei Zhang; Qing-Bin Lu; Zhen-Dong Yang; Qin-Lin Xin; Ya-Bin Song; Xiao-Ai Zhang; Hai-Zhou Liu; Juan Du; Xue-Juan Fan; Lan Yuan; Yi-Mei Yuan; Zhen Wang; Juan Wang; Lan Zhang; Dong-Na Zhang; Zhi-Bo Wang; Ke Dai; Jie-Ying Bai; Zhao-Nian Hao; Hang Fan; Li-Qun Fang; Gengfu Xiao; Yang Yang; Ke Peng; Hong-Quan Wang; Jian-Xiong Li; Lei-Ke Zhang; Wei Liu
Journal:  Signal Transduct Target Ther       Date:  2021-04-16

Review 5.  A systematic review of whether COVID-19 randomized controlled trials reported on demographic and clinical characteristics.

Authors:  Joyce Pak; Jennifer L Lund; Alexander Keil; Daniel Westreich; Til Stürmer; David Wohl; Claire Farel; M Bradley Drummond; Michael Webster-Clark
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-08-22       Impact factor: 2.732

6.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.

Authors:  Travis K Warren; Robert Jordan; Michael K Lo; Adrian S Ray; Richard L Mackman; Veronica Soloveva; Dustin Siegel; Michel Perron; Roy Bannister; Hon C Hui; Nate Larson; Robert Strickley; Jay Wells; Kelly S Stuthman; Sean A Van Tongeren; Nicole L Garza; Ginger Donnelly; Amy C Shurtleff; Cary J Retterer; Dima Gharaibeh; Rouzbeh Zamani; Tara Kenny; Brett P Eaton; Elizabeth Grimes; Lisa S Welch; Laura Gomba; Catherine L Wilhelmsen; Donald K Nichols; Jonathan E Nuss; Elyse R Nagle; Jeffrey R Kugelman; Gustavo Palacios; Edward Doerffler; Sean Neville; Ernest Carra; Michael O Clarke; Lijun Zhang; Willard Lew; Bruce Ross; Queenie Wang; Kwon Chun; Lydia Wolfe; Darius Babusis; Yeojin Park; Kirsten M Stray; Iva Trancheva; Joy Y Feng; Ona Barauskas; Yili Xu; Pamela Wong; Molly R Braun; Mike Flint; Laura K McMullan; Shan-Shan Chen; Rachel Fearns; Swami Swaminathan; Douglas L Mayers; Christina F Spiropoulou; William A Lee; Stuart T Nichol; Tomas Cihlar; Sina Bavari
Journal:  Nature       Date:  2016-03-02       Impact factor: 49.962

Review 7.  Fc receptors in antibody-dependent enhancement of viral infections.

Authors:  Adam Taylor; Suan-Sin Foo; Roberto Bruzzone; Luan Vu Dinh; Nicholas J C King; Suresh Mahalingam
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.